Expression Changes of CX3CL1 and Interleukin-6 Genes During Remission Induction Therapy in Patients with Acute Myeloid Leukemia
DOI:
https://doi.org/10.31661/gmj.v10i.2288Keywords:
CX3CL-1, IL-6, Remission Therapy, Acute Myeloid LeukemiaAbstract
Background: Acute myeloid leukemia (AML) syndrome is a hematologic malignancy due to the extensive clonal proliferation of leukemic precursor cells and is rapidly fatal unless treated or in response to chemotherapy. Cytogenetic findings have an important role in the prognosis and categorization of AML. This study aimed to investigate the expression changes in CX3CL1 and Interleukin-6 (IL-6) genes before and after chemotherapy as remission induction therapy in AML patients. Materials and Methods: In this study, 69 patients (36 males, 33 female) with AML were selected from tertiary medical health centers. A quantitative polymerase chain reaction was performed for mRNA expression of CX3CL1 and IL-6 genes before and after induction chemotherapy using the 2-ΔΔCT method. Results: The expression of CX3CL1 and IL-6 were significantly increased after induction chemotherapy. Also, the ΔCt mean of CX3CL1 and IL-6 mRNA was not significant between AML subtype groups. Conclusion: We showed that chemotherapy significantly increases the expression of CX3CL1 and IL-6, which can be used as a prognostic factor of AML. [GMJ.2021;10:e2288]
References
Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74. https://doi.org/10.1182/blood-2009-07-235358PMid:19880497 Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Investig. 2003;21(6):873-86. https://doi.org/10.1081/CNV-120025091PMid:14735692 Estey EH. General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin Hematol.2006; 43(2): 89-95. https://doi.org/10.1053/j.seminhematol.2006.01.002PMid:16616042 Mavromatis B, Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukemia. J Clin Oncol. 2003;21(9):1874-81. https://doi.org/10.1200/JCO.2003.09.113PMid:12721266 Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111(12):5486-95. https://doi.org/10.1182/blood-2007-10-117671PMid:18390837 Ibrahem L, Mahfouz R, Elhelw L, Abdsalam EM, Soliman R. Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia. Blood Cells Mol Dis. 2015;54(1):84-9. https://doi.org/10.1016/j.bcmd.2014.07.015PMid:25172541 Li K, Lv XX, Hua F, Lin H, Sun W, Cao WB et al. Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a tollâ€like receptor 2â€mediated cellâ€penetrating peptide. Int J Cancer Res. 2014;134(3):692-702. https://doi.org/10.1002/ijc.28382PMid:23852533 Nasrollahi SA, Taghibiglou C, Azizi E, Farboud ES. Cellâ€penetrating peptides as a novel transdermal drug delivery system. Chem Biol Drug Des. 2012;80(5):639-46. https://doi.org/10.1111/cbdd.12008PMid:22846609 Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. NEJM. 2006;354(6):610-21. https://doi.org/10.1056/NEJMra052723PMid:16467548 Verge GM, Milligan ED, Maier SF, Watkins LR, Naeve GS, Foster AC. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci. 2004;20(5):1150-60. https://doi.org/10.1111/j.1460-9568.2004.03593.xPMid:15341587 Corcione A, Ferretti E, Pistoia V. CX3CL1/fractalkine is a novel regulator of normal and malignant human B cell function. J Leukoc Biol. 2012;92(1):51-8. https://doi.org/10.1189/jlb.0112035PMid:22457367 D'Haese JG, Demir IE, Friess H, Ceyhan GO. Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther. Targets. 2010;14(2):207-19. https://doi.org/10.1517/14728220903540265PMid:20055718 Sugiyama H, Inoue K, Ogawa H, Yamagami T, Soma T, Miyake S et al. The expression of IL-6 and its related genes in acute leukemia. Leuk Lymphoma. 1996;21(1-2):49-52. https://doi.org/10.3109/10428199609067579PMid:8907269 Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogenâ€activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology. 1999;30(5):1128-33. https://doi.org/10.1002/hep.510300522PMid:10534331
